TY - JOUR
T1 - Mycobacterium tuberculosis-reactive CD8+ T lymphocytes
T2 - The relative contribution of classical versus nonclassical HLA restriction
AU - Lewinsohn, David M.
AU - Briden, Andria L.
AU - Reed, Steven G.
AU - Grabstein, Kenneth H.
AU - Alderson, Mark R.
PY - 2000/7/15
Y1 - 2000/7/15
N2 - Previous studies in mice and humans models have suggested an important role for CD8+ T cells in host defense to Mycobacterium tuberculosis (Mtb). In humans, CD8+ Mtb-reactive T cells have been described that are HLA-A2-, B52-, as well as CD1-restricted. Recently, we have described Mtb-specific CD8+ T cells that are neither HLA-A-, B-, or C- nor group 1 CD1-restricted. At present, little is known about the relative contribution of each of these restriction specificities to the overall CD8+ response to Mtb. An IFN-γ enzyme-linked immunospot assay was used to determine the frequency of Mtb- reactive CD8+ T cells directly from PBMC. The effector cell frequency among five healthy purified protein derivative-positive subjects was 1/7,600 ± 4,300 compared with 1/16,000 ± 7,000 in six purified protein derivative- negative controls. To determine the frequencies of classically, CD1-, and nonclassically restricted cells, a limiting dilution analysis was performed. In one purified protein derivative-positive subject, 192 clones were generated using Mtb-infected dendritic cells (DC). Clones were assessed for reactivity against control autologous DC, Mtb-infected autologous DC, and HLA-mismatched CD1+ targets (DC), as well as HLA-mismatched CD1+ targets (macrophages). Of the 96 Mtb-reactive CD8+ T cell clones, four (4%) were classically restricted and 92 (96%) were nonclassically restricted. CD1- restricted cells were not detected. Of the classically restricted cells, two were HLA-B44 restricted and one was HLA-B14 restricted. These results suggest that while classically restricted CD8+ lymphocytes can be detected, they comprise a relatively small component of the overall CD8+ T cell response to Mtb. Further definition of the nonclassical response may aid development of an effective vaccine against tuberculosis.
AB - Previous studies in mice and humans models have suggested an important role for CD8+ T cells in host defense to Mycobacterium tuberculosis (Mtb). In humans, CD8+ Mtb-reactive T cells have been described that are HLA-A2-, B52-, as well as CD1-restricted. Recently, we have described Mtb-specific CD8+ T cells that are neither HLA-A-, B-, or C- nor group 1 CD1-restricted. At present, little is known about the relative contribution of each of these restriction specificities to the overall CD8+ response to Mtb. An IFN-γ enzyme-linked immunospot assay was used to determine the frequency of Mtb- reactive CD8+ T cells directly from PBMC. The effector cell frequency among five healthy purified protein derivative-positive subjects was 1/7,600 ± 4,300 compared with 1/16,000 ± 7,000 in six purified protein derivative- negative controls. To determine the frequencies of classically, CD1-, and nonclassically restricted cells, a limiting dilution analysis was performed. In one purified protein derivative-positive subject, 192 clones were generated using Mtb-infected dendritic cells (DC). Clones were assessed for reactivity against control autologous DC, Mtb-infected autologous DC, and HLA-mismatched CD1+ targets (DC), as well as HLA-mismatched CD1+ targets (macrophages). Of the 96 Mtb-reactive CD8+ T cell clones, four (4%) were classically restricted and 92 (96%) were nonclassically restricted. CD1- restricted cells were not detected. Of the classically restricted cells, two were HLA-B44 restricted and one was HLA-B14 restricted. These results suggest that while classically restricted CD8+ lymphocytes can be detected, they comprise a relatively small component of the overall CD8+ T cell response to Mtb. Further definition of the nonclassical response may aid development of an effective vaccine against tuberculosis.
UR - http://www.scopus.com/inward/record.url?scp=0034661720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034661720&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.165.2.925
DO - 10.4049/jimmunol.165.2.925
M3 - Article
C2 - 10878367
AN - SCOPUS:0034661720
SN - 0022-1767
VL - 165
SP - 925
EP - 930
JO - Journal of Immunology
JF - Journal of Immunology
IS - 2
ER -